[Immunological and epidemiological effectiveness of the HEVAC B vaccine against hepatitis B in a group at enhanced risk of infection].
The immunological and epidemiological effectiveness of HEVAC B vaccine against hepatitis B (Pasteur Institute, France) was studied in 215 medical workers of Moscow who had contacts with the blood or preparations thereof. A control group consisted of 155 medical workers. The groups were formed randomly but both included the subjects without HBsAg and anti-HBs. The HEVAC B vaccine was found to be characterized by high immunologic efficacy. Administration of the vaccine induced seroconversion after the 1st, 2nd, and 3rd vaccinations in 36.3%, 77.2%, and 93.9% vaccinees, respectively. In the course of immunization, a marked rise of specific antibody levels was observed. Among the vaccinees no cases of hepatitis B with jaundice were recorded, while in the control group there were 2 cases (1.3%). The vaccine has a low reactogenicity and is safe for use.
D000293:Adolescent; D000328:Adult; D004341:Drug Evaluation; D005260:Female; D006509:Hepatitis B / Q000517:prevention & control*; D006510:Hepatitis B Antibodies / Q000032:analysis; D006801:Humans; D008297:Male; D008505:Medical Staff, Hospital; D008875:Middle Aged; D009031:Moscow; D012306:Risk; D013997:Time Factors; D014761:Viral Hepatitis Vaccines / Q000008:administration & dosage / Q000009:adverse effects / Q000276:immunology*
D006510:Hepatitis B Antibodies; D014761:Viral Hepatitis Vaccines
Izuchenie immunologicheskoĭ i épidemiologicheskoĭ éffektivnosti vaktsiny HEVAC B protiv gepatita B v gruppe povyshennogo riska zarazheniia.